Researcher.Life Logo

CNS Neuroscience and Therapeutics : Impact Factor & More

eISSN: 1755-5949pISSN: 1755-5930
JournalOpen Access

Aims and Scope of CNS Neuroscience and Therapeutics

CNS Neuroscience & Therapeutics is a bimonthly medical journal published 1995 by Wiley-Blackwell addressing topics in neurology and central nervous system therapeutic pharmacology. It was established in 1995 as CNS Drug Reviews and obtained its current title in 2008. Less

Key Metrics

CiteScore
8.9
Eigenfactor
0.005 - 0.01
Impact Factor
5 - 10
SJR
Q1Pharmacology
SNIP
1.34
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on CNS Neuroscience and Therapeutics

CNS Neuroscience and Therapeutics Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher WILEY
Language English
Frequency Monthly
Article Processing ChargesEUR 2150 | GBP 1900 | USD 2530
Publication Time14
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1995
Publisher URLVisit website
Website URLVisit website
Publication Details
Other chargesVisit website
PlagiarismVisit website
Publication Time 14
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY
OA statementVisit website
View less

Planning to publish in CNS Neuroscience and Therapeutics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in CNS Neuroscience and Therapeutics

Development and Validation of Multiple Machine Learning Models Integrating Neutrophil‐Lymphocyte Ratio for Prediction of Hemorrhagic Transformation After Intravenous Thrombolysis in Acute Ischemic Stroke
  • 12 Dec 2025
  • CNS Neuroscience & Therapeutics
Activation and Long‐Term Maintenance of Adaptive Immunity in the Central Nervous System: A Double‐Edged Sword?
  • 12 Dec 2025
  • CNS Neuroscience & Therapeutics
Cellular Communication Networks Mediated by Microglia in Ischemic Stroke
  • 9 Dec 2025
  • CNS Neuroscience & Therapeutics
Perfusion and Structural Impairment in Minor Stroke and Transient Ischemic Attack With Intracranial Atherosclerotic Stenosis: Associations With Cognitive Decline
  • 9 Dec 2025
  • CNS Neuroscience & Therapeutics
Phase 2 Trial of PD‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma
  • 8 Dec 2025
  • CNS Neuroscience & Therapeutics
Mfsd2a‐Targeted Therapy for Ischemic Stroke: Mechanisms, Evidence, and Future Prospects
  • 8 Dec 2025
  • CNS Neuroscience & Therapeutics
Development and Validation of Multiple Machine Learning Models Integrating Neutrophil‐Lymphocyte Ratio for Prediction of Hemorrhagic Transformation After Intravenous Thrombolysis in Acute Ischemic Stroke
  • 12 Dec 2025
  • CNS Neuroscience & Therapeutics
Activation and Long‐Term Maintenance of Adaptive Immunity in the Central Nervous System: A Double‐Edged Sword?
  • 12 Dec 2025
  • CNS Neuroscience & Therapeutics
Cellular Communication Networks Mediated by Microglia in Ischemic Stroke
  • 9 Dec 2025
  • CNS Neuroscience & Therapeutics
Perfusion and Structural Impairment in Minor Stroke and Transient Ischemic Attack With Intracranial Atherosclerotic Stenosis: Associations With Cognitive Decline
  • 9 Dec 2025
  • CNS Neuroscience & Therapeutics
Phase 2 Trial of PD‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma
  • 8 Dec 2025
  • CNS Neuroscience & Therapeutics
Mfsd2a‐Targeted Therapy for Ischemic Stroke: Mechanisms, Evidence, and Future Prospects
  • 8 Dec 2025
  • CNS Neuroscience & Therapeutics

FAQs on CNS Neuroscience and Therapeutics